已发表急性呼吸衰竭危重患者初始通气策略随机对照试验的类型学:方法学综述
该研究检索了1995年1月至2019年12月间发表的74项针对成人急性呼吸衰竭的随机对照试验,主要比较氧合/通气策略(95%),其中57%为单中心试验,20%提前终止。共使用22种不同的主要终点,49%的试验以呼吸事件为主要终点(其中76%为插管),29%使用生理/临床终点,12%使用死亡率。总体42项试验(57%)为阳性:呼吸事件终点试验中52%阳性,生理/临床终点试验中76%阳性,死亡率终点试验中33%阳性。校正研究质量后,与阳性试验相关的因素包括基于临床的主要终点(OR 8.40,95%CI 1.35-65.79)、使用标准化急性呼吸衰竭管理(OR 4.55,95%CI 1.02-22.88)和单中心试验(OR 3.85,95%CI 1.25-13.11)。
要点
- 74项急性呼吸衰竭通气策略随机对照试验中,57%为单中心试验,20%提前终止。
- 22种不同主要终点中,49%的试验使用呼吸事件终点(其中76%为插管),29%使用生理/临床终点,12%使用死亡率。
- 生理/临床终点试验阳性率76%,呼吸事件终点试验阳性率52%,死亡率终点试验阳性率33%。
- 校正研究质量后,与阳性试验相关的因素包括临床主要终点(OR 8.40,95%CI 1.35-65.79)、标准化急性呼吸衰竭管理(OR 4.55,95%CI 1.02-22.88)和单中心试验(OR 3.85,95%CI 1.25-13.11)。
适用人群与场景
- 成人急性呼吸衰竭患者,包括各种病因(占62%的试验中患者病因各异)。
研究设计与关键结果
- 共纳入74项随机对照试验,其中57%为单中心试验,95%比较氧合/通气策略,62%的试验患者急性呼吸衰竭病因各异,20%的试验提前终止。
- 24项试验(32%)采用了标准化急性呼吸衰竭管理。
- 共使用22种不同的主要终点:呼吸事件终点用于44项试验(49%),其中76%为插管;生理/临床终点用于21项试验(29%);死亡率终点用于9项试验(12%)。
- 总体42项试验(57%)为阳性:呼吸事件终点试验中52%阳性,生理/临床终点试验中76%阳性,死亡率终点试验中33%阳性。
- 校正研究质量(Cochrane偏倚风险工具)后,与阳性试验相关的因素包括基于临床的主要终点(OR 8.40,95%CI 1.35-65.79)、使用标准化急性呼吸衰竭管理(OR 4.55,95%CI 1.02-22.88)和单中心试验(OR 3.85,95%CI 1.25-13.11)。
证据类型、等级与局限
- 证据类型:方法学综述,检索MEDLINE、Cochrane Central Register of Controlled Trials和Web of Science,纳入1995年1月至2019年12月发表的随机对照试验,使用Cochrane偏倚风险工具评估研究质量。
- 局限:原文未报告局限性。
对床旁实践的改变
- 已发表急性呼吸衰竭初始通气策略随机对照试验的类型学可用于构建该领域未来试验设计,并指导临床医生和研究人员将研究最佳转化为床旁实践(作者认为)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Randomized controlled trials (RCTs) in patients with hypoxemic acute respiratory failure (ARF) often failed to show survival benefits and resulted in varying clinical end points.
RESEARCH QUESTION: This methodologic review was conducted of published RCTs on ARF, with a careful attention to whether the study results were positive or negative.
STUDY DESIGN AND METHODS: MEDLINE, Cochrane Central Register of Controlled Trials, and Web of Science were searched for published RCTs in adult patients with ARF between January 1995 and December 2019. The objective was to investigate sources of heterogeneity and factors associated with a positive RCT (ie, with a significant difference on the primary end point). To determine the importance of the primary end point choice, end points were classified as follows: (1) respiratory event end points (corresponding to modification of the ventilation support); (2) physiologic/clinical end points (corresponding to oxygenation or clinical parameters); and (3) mortality. The Cochrane risk-of-bias tool was used to assess study quality.
RESULTS: Seventy-four RCTs were included (57% were single-center RCTs) comparing mainly oxygenation/ventilation strategies (95%) in patients with various ARF causes (62%); studies were stopped prematurely in 20% of the trials. A standardized management of ARF was observed in 24 (32%) trials. Twenty-two distinct primary end points have been used, the first of which were those based on respiratory events (44 RCTs [49%]), namely intubation in 76% of the cases. Physiologic/clinical end points have been used in 21 trials (29%) and mortality in nine (12%). Overall, 42 (57%) RCTs were positive, 52% in studies with respiratory event end points, 76% in studies with physiologic/clinical end points, and 33% in studies with mortality end points. Adjusted for study quality (Cochrane risk-of-bias tool), factors associated with a positive RCT included clinically based primary end points (OR, 8.40; 95% CI, 1.35-65.79), the use of standardized ARF management (OR, 4.55; 95% CI, 1.02-22.88), and single-center trials (OR, 3.85; 95% CI, 1.25-13.11).
INTERPRETATION: The typology of published RCTs in patients with ARF could be used to frame future trial designs in this field and guide clinicians and researchers toward optimal research transfer to the bedside.
参考来源
- Dumas G, Chevret S, Le Corre M, et al. Typology of Published Randomized Controlled Trials Investigating Initial Ventilation Strategy in Critically Ill Patients With Acute Respiratory Failure: A Methodologic Review. Chest. 2020. PMID: 32387523. doi:10.1016/j.chest.2020.03.082
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。